Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 3;29(11):3103-3106.
doi: 10.1016/j.ymthe.2021.10.019. Epub 2021 Oct 28.

Imagine CRISPR cures

Fyodor D Urnov  1
Affiliations

Imagine CRISPR cures

Fyodor D Urnov. Mol Ther. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
The path from a lethal mutation to a CRISPR therapeutic (A) The genic context of, and genome editing reagents for, the mutation that killed the infant treated by Lev et al. The mutation (mutant allele, shown, is an A; wild-type allele is a G) drives aberrant splicing of LCP2 (genomic coordinates in hg38 are indicated). The gRNA spacer for DSB-driven editing and the cognate ODN repair template, are shown below the sequence. The ODN specifies the correct allele (highlighted in red); the ODN does not contain a “PAM-blocking” mutation because the SNP lies in the “seed” region. (B) An accelerated timeline to engineering, derisking, and putting through regulatory review an edited HPSC product to treat terminally ill pediatric subjects such as the one described by Lev et al. Every step in the process will require formidable scientific and regulatory innovation; a realistic, actionable path to such innovation exists across the entire problem space.
See this image and copyright information in PMC

References

    1. Owen M.J., Niemi A.-K., Dimmock D.P., Speziale M., Nespeca M., Chau K.K., Van Der Kraan L., Wright M.S., Hansen C., Veeraraghavan N. Rapid sequencing-based diagnosis of thiamine metabolism dysfunction syndrome. N. Engl. J. Med. 2021;384:2159–2161. - PMC - PubMed
    1. Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816–821. - PMC - PubMed
    1. Frangoul H., Altshuler D., Cappellini M.D., Chen Y.-S., Domm J., Eustace B.K., Foell J., de la Fuente J., Grupp S., Handgretinger R. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N. Engl. J. Med. 2021;384:252–260. - PubMed
    1. Gillmore J.D., Gane E., Taubel J., Kao J., Fontana M., Maitland M.L., Seitzer J., O’Connell D., Walsh K.R., Wood K. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 2021;385:493–502. - PubMed
    1. Kohn D.B., Booth C., Shaw K.L., Xu-Bayford J., Garabedian E., Trevisan V., Carbonaro-Sarracino D.A., Soni K., Terrazas D., Snell K. Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency. N. Engl. J. Med. 2021;384:2002–2013. - PMC - PubMed

LinkOut - more resources